Heart Failure Milestones in Management: 9 Studies Making a Difference in 2021

SGLT-2 inhibitors have proven effective in disease modification as well as symptom improvement across HF phenotypes and severity. Get a quick summary of the research.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have proven effective in disease modification and symptom improvement across heart failure (HF) phenotypes and severity with results of recent landmark clinical trials laying groundwork for FDA approval and updates to clinical practice guidelines.

Other findings released in 2021 shed light on factors that both worsen and improve HF-associated morbidity and mortality. Highlights of 9 notable studies follow in the slide show below.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2023 MJH Life Sciences

All rights reserved.